Equinox Group’s OncoScreen offering provides a suite of tools to evaluate emerging cancer therapies. The decision maker who evaluates the commercial outlook for oncology drugs in development faces unique challenges, including:

• Target patients who, for any tumor type, are highly segmented by stage of disease, prognostic markers, previous treatment, and other factors
  
  
• New therapeutics that can potentially treat multiple tumor types
  
  
• New agents that can be added to multidrug regimens
  
  
• Many new anticancer drugs in development have novel mechanisms of action with limited clinical data and no comparable analogs
  
  
• Some developmental anticancer agents have the potential to profoundly alter the future competitive landscape

Sample OncoScreen Revenue Outputs

OncoScreen Solves the Important Challenges in Oncology New Product Forecasting

OncoScreen builds on well-established methods (e.g., unmet need analysis to measure product innovation) that Equinox Group has created for evaluating new drugs in other therapeutic areas. It provides customized tools to solve the problems decision makers confront when evaluating oncology agents/regimens.

• Links an agent’s expected clinical attributes directly to predicted share of patients in a transparent and defensible manner
  
  
• Uses an oncology-specific Equinox Share Predictor (ESP) forecasting algorithm, based on analysis of recent launches in the cancer market, that estimates the peak-year share of patients the client’s agent is likely to achieve as a function of: 1) its clinical improvement compared to the gold standard, and 2) the number of competing therapies it will face in the market
  
  
• Forecasts share and revenue by tumor type, line of therapy, and country (customized to the client’s need)
  
  
• Takes developmental competitors’ clinical attributes, launch dates, and angles of impact (i.e., how directly a competitor will compete with the client’s agent) into account to predict share of each developmental competitor


• Differentiates share impact of a label, compendium listing, or publication strategy, by line of therapy and by country
  
  
• Models new agents in monotherapy or as part of a multidrug regimen
  
  
• Allows for clinical assumptions about the client’s agent and those of its competitors to be easily updated and reflected in the forecast